ALIVUS — Alivus Life Sciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual income statement for Alivus Life Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	21,232	21,612	22,832	23,869	25,518
Cost of Revenue
Gross Profit	10,803	11,471	12,812	12,878	14,853
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	15,440	15,605	16,611	17,631	18,556
Operating Profit	5,792	6,008	6,221	6,238	6,963
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5,649	6,286	6,313	6,541	7,513
Provision for Income Taxes
Net Income After Taxes	4,187	4,670	4,709	4,856	5,645
Net Income Before Extraordinary Items
Net Income	4,187	4,670	4,709	4,856	5,645
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,187	4,670	4,709	4,856	5,645
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	35.7	38.1	38.4	39.6	47.5
Dividends per Share